Company intelligence / Profile preview
Praetego
Durham, North Carolina, United Statespraetego.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Praetego’s lead candidate PTG‑630 has demonstrated neuroprotection in preclinical models of AD and DPN, showing protection against mild cognitive impairment and biomarker evidence of neuronal benefit. IND-enabling studies are ongoing with an IND filing planned for late 2024. The company has received multiple NIH grants to advance its programs toward clinical trials.
A Phase 2 study will target diabetics with mild cognitive impairment at high risk for AD to demonstrate target engagement and proof of mechanism.
Additional preclinical work supports expansion into diabetic retinopathy as a third indication.
No human clinical results reported yet.- Therapeutic areas
- OphthalmologyEndocrinologyNeurology
- Modalities
- Small molecules (Amadorins)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with Penn State University on diabetic retinopathy researchCollaboration with University of California at San Diego School of Medicine on CNS diseases
Beyond the preview
Go deeper on Praetego.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Praetego.